Impact of oral versus intravenous ibuprofen on neurodevelopmental outcome: a randomized controlled parallel study.
OBJECTIVE
Although neurodevelopmental outcomes related to the management of patent ductus arteriosus with intravenous indomethacin and ibuprofen are known, little data on the long-term effects of oral ibuprofen can be found in the literature.


METHODS
A follow-up study of 99 infants with birth weight ≤ 1,500 g and gestational age ≤ 32 weeks who received either oral or intravenous ibuprofen for patent ductus arteriosus was conducted to assess at 18 to 24 months (corrected age), abnormal neurological, neurosensory, and cognitive impairment were defined as follows:neurological outcomes included moderate/severe cerebral palsy, neurosensory outcomes included bilateral hearing loss and blindness in either eye, and cognitive impairment included mental developmental index score < 70.


RESULTS
The 18- to 24-month (corrected age) long-term outcomes of 30 subjects who received oral ibuprofen were compared with 27 subjects who received intravenous ibuprofen by certified and experienced examiners who were blind to the definitions of the groups. The results revealed that the long-term outcomes of the treatment regimens did not significantly differ.


CONCLUSIONS
Preterm infants who were treated with oral ibuprofen for patent ductus arteriosus had similar neurological, neurosensory, and cognitive outcomes to patients who received intravenous ibuprofen at 2 years of age.
Developmental Behavioral Pediatrics Unit of Developmental Behavioral Pediatrics, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.
Zeynep
Z
Eras
Tulin
T
Gokmen
Omer
O
Erdeve
Banu Mutlu
BM
Ozyurt
Bagdagul
B
Saridas
Ugur
U
Dilmen
D061605:Administration, Intravenous; D000284:Administration, Oral; D001766:Blindness / Q000209:etiology; D016022:Case-Control Studies; D002547:Cerebral Palsy / Q000209:etiology; D002657:Child Development / Q000187:drug effects*; D003072:Cognition Disorders / Q000209:etiology; D004374:Ductus Arteriosus, Patent / Q000150:complications / Q000188:drug therapy*; D006312:Hearing Loss, Bilateral / Q000209:etiology; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage* / Q000009:adverse effects; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature / Q000254:growth & development*; D019102:Infant, Very Low Birth Weight / Q000254:growth & development*; D016015:Logistic Models; D012307:Risk Factors
D007052:Ibuprofen